What Are Biopharmaceutical Excipients? Defining the Shift from Oral Solids to Injectable Stabilizers

Biopharmaceutical excipients are the inactive substances added to biologic drug products to protect large, structurally fragile biomolecules, such as monoclonal antibodies (mAbs), vaccines, messenger RNA (mRNA), and viral vectors, from degradation during manufacturing, shipping, and storage. Unlike excipients in oral solid dosage forms, which primarily serve mechanical functions like binding, filling, and disintegrating tablets, biopharmaceutical excipients act as molecular stabilizers, surfactants, cryoprotectants, and tonicity agents that keep proteins correctly folded, prevent aggregation at interfaces, and maintain product integrity under the stresses of freeze-thaw, agitation, and long-term shelf life.

The global biopharmaceutical excipients market reached an estimated USD 2.43 billion in 2024 and is projected to grow to USD 3.76 billion by 2032.[1] With over 100 monoclonal antibodies approved by the US Food and Drug Administration (FDA) and rapid expansion into mRNA therapeutics, antibody-drug conjugates (ADCs), and gene therapies, the role of excipients in biologic formulations has become one of the most technically demanding disciplines in pharmaceutical science.

Table of Contents

• Why Biopharmaceutical Excipients Differ from Oral Solid Dosage Excipients
• Functional Categories of Biopharmaceutical Excipients
• Buffers: Maintaining pH for Protein Stability
• Stabilizers, Cryoprotectants, and Lyoprotectants
• Surfactants: Preventing Interfacial Aggregation
• Amino Acids: Viscosity Reduction and Antioxidant Protection
• Tonicity Agents and Chelators
• How Excipients Protect Biologic Molecules: Key Stabilization Mechanisms
• Excipient Profiles in Commercial Monoclonal Antibody Formulations
• Excipients Across Biologic Modalities: mRNA/LNP, ASOs, ADCs, AAVs, and Cell Therapies
• Polysorbate Degradation: The Defining Quality Challenge
• Quality Grades for Parenteral and Biologics Applications
• Regulatory Framework for Biopharmaceutical Excipients
• Comparison: Oral Solid Dosage Excipients vs. Biopharmaceutical Excipients
• Supplier Landscape for Biologics-Grade Excipients
• FAQs
• Key Takeaways
• Sources

Why Biopharmaceutical Excipients Differ from Oral Solid Dosage Excipients

Biopharmaceutical excipients serve a fundamentally different purpose than excipients in conventional oral solid dosage forms. In a tablet, excipients such as microcrystalline cellulose, magnesium stearate, or croscarmellose sodium provide mechanical bulk, aid powder flow, enable compression, and control disintegration. The active pharmaceutical ingredient (API) in a tablet is typically a small molecule (molecular weight under 1,000 Da) that is chemically robust and tolerant of heat, pressure, and dry conditions.

Biologic APIs, by contrast, are large, three-dimensional proteins or nucleic acids with molecular weights ranging from approximately 25,000 Da for a single-chain antibody fragment to over 150,000 Da for a full-length immunoglobulin G (IgG) monoclonal antibody. These molecules rely on precise tertiary and quaternary structure for their therapeutic function. Even subtle conformational changes, such as partial unfolding at an air-liquid interface, can trigger irreversible aggregation, loss of potency, and immunogenicity risk. Biopharmaceutical excipients exist to prevent these structural failures across every stage of a biologic product’s lifecycle, from bulk drug substance hold through fill-finish, frozen storage, thawing, shipping, and patient administration.[2]

See and download our infographic on Biopharmaceutical Excipients:

Functional Categories of Biopharmaceutical Excipients

Biopharmaceutical excipients fall into several functional categories, each addressing a specific physicochemical stress or formulation requirement. The table below summarizes the primary categories, their mechanisms, and commonly used representatives.

Table 1. Functional Categories of Biopharmaceutical Excipients

Category	Primary Function	Common Representatives	Typical Use Level
Buffers	Maintain pH within target range (typically pH 5.0–7.5)	Histidine, phosphate, citrate, acetate, Tris	10–50 mM
Stabilizers / cryoprotectants / lyoprotectants	Thermodynamic stabilization of protein conformation; protect during freeze-thaw and lyophilization	Sucrose, trehalose, mannitol, sorbitol, glycine	1–10% w/v
Surfactants	Prevent protein aggregation at air-liquid and ice-liquid interfaces	Polysorbate 80 (PS80), polysorbate 20 (PS20), poloxamer 188	0.001–0.1% w/v
Amino Acids (Buffers)	Reduce viscosity, provide antioxidant protection, enhance colloidal stability	Arginine, methionine, proline, glycine	10–200 mM
Tonicity agents	Adjust osmolality to physiological range (~300 mOsm/kg)	Sodium chloride, sugars	50–150 mM
Chelators	Sequester trace metals that catalyze oxidation	Ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA)	0.05–0.5 mM
LNP components (mRNA)	Encapsulate and deliver nucleic acid cargo	Ionizable lipids, PEG-lipids, cholesterol, helper phospholipids	Defined by mol% ratios

Buffers: Maintaining pH for Protein Stability

Buffers in biopharmaceutical formulations maintain the solution pH within the narrow range required for protein conformational stability and minimal chemical degradation. Histidine has become the most widely used buffer in marketed monoclonal antibody formulations, appearing in approximately 82% of high-concentration antibody drug products approved in the United States.[3] Histidine offers a favorable pKa of approximately 6.0, making it suitable for the pH 5.5–6.5 range common in subcutaneous (SC) mAb formulations. Beyond buffering, histidine contributes to protein stabilization through electrostatic repulsion between protein molecules, which reduces self-association and lowers solution viscosity, a critical advantage for high-concentration SC delivery.[3]

Sodium phosphate buffers remain common in intravenous (IV) formulations but carry a significant limitation for frozen or lyophilized products: phosphate buffers undergo substantial pH shifts during freezing due to selective crystallization of the dibasic salt, which can destabilize pH-sensitive proteins. Non-phosphate buffers such as histidine, citrate, and Tris are preferred alternatives for products that undergo freeze-thaw or lyophilization cycles.[2]

Stabilizers, Cryoprotectants, and Lyoprotectants

Stabilizers protect biologic molecules from thermal, mechanical, and dehydration-induced stresses. The most important stabilizers in biologics formulations are disaccharides, primarily sucrose and trehalose, which serve dual roles as cryoprotectants (protecting during freezing) and lyoprotectants (protecting during the drying step of lyophilization).

Sucrose is the most commonly used stabilizer in marketed monoclonal antibody products, present in over 53% of commercial mAb formulations as of recent surveys.[3,4] Trehalose serves as a functionally similar alternative and is found in approximately 12% of high-concentration antibody products.[3] Both disaccharides stabilize proteins through the preferential exclusion mechanism first described by Timasheff: the sugar molecules are thermodynamically excluded from the protein surface, increasing the free energy of the unfolded state relative to the native state, thereby shifting the equilibrium toward the correctly folded conformation.[2]

For lyophilized products, mannitol and glycine function as bulking agents that form a mechanically robust cake structure, while sucrose or trehalose serves as the lyoprotectant that replaces hydrogen bonds lost when water is removed during drying.[5]

Surfactants: Preventing Interfacial Aggregation

Surfactants are among the most critical and most studied excipients in biologic formulations. Polysorbate 80 (PS80) is the most widely used surfactant in mAb products, followed by polysorbate 20 (PS20) and poloxamer 188. Collectively, polysorbates appear in approximately 95% of high-concentration antibody drug products.[3]

Surfactants protect proteins by competing with protein molecules for adsorption at hydrophobic interfaces, including air-liquid, ice-liquid, and solid-liquid (e.g., primary packaging surfaces) boundaries. Without surfactant, protein molecules adsorb to these interfaces, undergo partial unfolding, and form insoluble aggregates and subvisible particles.[6] During manufacturing, proteins encounter interfacial and shear stress at multiple unit operations: thawing of frozen drug substance, mixing with additional excipients, pumping through fill-finish equipment, and administration through needles and autoinjectors.[6]

Surfactant concentrations in biologic formulations are typically low (0.001–0.1% w/v) because the goal is interfacial coverage, not bulk solution properties. The optimal concentration balances adequate interface protection against the risk of surfactant-related degradation products (discussed in the polysorbate degradation section below) or irritation upon administration.

Amino Acids: Viscosity Reduction and Antioxidant Protection

Amino acids have become increasingly important excipients in biopharmaceutical formulations, particularly for high-concentration subcutaneous products where viscosity management is essential for syringeability and patient comfort.

Arginine is the most commonly used viscosity-reducing amino acid, present in approximately 27% of high-concentration mAb products.[3] Arginine reduces protein-protein attractive interactions by modulating electrostatic and hydrophobic forces between mAb molecules, thereby lowering solution viscosity at concentrations above 100 mg/mL.

Methionine serves as a sacrificial antioxidant, scavenging reactive oxygen species before they can oxidize susceptible amino acid residues (particularly methionine and tryptophan residues) on the protein molecule. Methionine appears in approximately 18% of high-concentration antibody formulations; reported concentrations range from below 1 mM to 25 mM depending on the product and oxidation risk profile.[3] Proline and glycine contribute to thermal stability and can serve as bulking agents in lyophilized formulations.

Tonicity Agents and Chelators

Tonicity agents adjust the osmolality of biopharmaceutical formulations to approximate physiological conditions (approximately 300 mOsm/kg), ensuring patient tolerability upon injection. Sodium chloride is the most straightforward tonicity agent, used in approximately 18% of high-concentration mAb products.[3] In many formulations, the stabilizing sugars (sucrose, trehalose) simultaneously contribute to osmolality, reducing or eliminating the need for additional tonicity adjustment.

Chelators such as EDTA and DTPA sequester trace metal ions (iron, copper) that catalyze oxidation reactions, particularly the metal-catalyzed oxidation of polysorbates and oxidation-sensitive amino acid residues on proteins. Typical parenteral formulation concentrations are 0.05–0.5 mM for Na2EDTA and 0.025–0.1 mM for DTPA. Chelators are particularly important in formulations containing polysorbate 80, where trace metals significantly accelerate oxidative degradation.[7]

See our video on biopharmaceutical excipients:

 

How Excipients Protect Biologic Molecules: Key Stabilization Mechanisms

Biopharmaceutical excipients protect biologic molecules through distinct physicochemical mechanisms. Understanding these mechanisms is essential for rational formulation design and for selecting excipient alternatives when compatibility issues arise.

Preferential Exclusion (Thermodynamic Stabilization)

Sugars, polyols, and certain amino acids stabilize proteins through preferential exclusion, originally characterized by Timasheff and colleagues. These excipients are excluded from the immediate hydration shell of the protein surface due to steric and thermodynamic effects. This exclusion increases the chemical potential of the protein in proportion to its exposed surface area. Because unfolded or aggregated protein has greater surface area than the native state, the presence of preferentially excluded excipients raises the free energy of unfolding, thermodynamically stabilizing the native conformation.[2]

Interfacial Competition (Surfactant Mechanism)

Polysorbates and poloxamers protect proteins by adsorbing preferentially to hydrophobic interfaces (air-liquid, ice-liquid, container surfaces). This competitive adsorption prevents protein molecules from reaching the interface, where partial unfolding and subsequent aggregation would occur. Research has demonstrated that interfacial stress, rather than shear stress alone, is the dominant driver of protein aggregation during manufacturing processes such as mixing, pumping, and filling.[6]

Colloidal Stabilization

Amino acids like arginine and lysine enhance electrostatic repulsion between protein molecules, reducing the probability of encounter and self-association. This mechanism is particularly important at high protein concentrations (>100 mg/mL), where intermolecular distances are short and attractive interactions (hydrophobic, electrostatic, dipole) can drive reversible self-association, elevated viscosity, and aggregation.[3]

Excipient Profiles in Commercial Monoclonal Antibody Formulations

Surveys of commercially approved monoclonal antibody products reveal clear patterns in excipient selection. The table below summarizes the frequency of key excipients in high-concentration antibody drug products approved in the United States.

Table 2. Excipient Frequency in US-Approved High-Concentration Monoclonal Antibody Products

Excipient	Frequency in High-Conc. mAb Products	Primary Role
Polysorbate (PS20 or PS80)	~94%	Surfactant
Histidine	~82%	Buffer
Sucrose	~48–53%	Stabilizer / lyoprotectant
Arginine	~27%	Viscosity reducer
Sodium chloride	~18%	Tonicity agent
Methionine	~18%	Antioxidant
Acetate	~12%	Buffer
Trehalose	~12%	Stabilizer / lyoprotectant

Data compiled from Svilenov et al. (2023) and recent quantitative surveys of marketed mAb formulations.[3,4]

Two formulation archetypes have emerged:

• High-concentration subcutaneous formulations preferentially use histidine buffer, sucrose, arginine, methionine, and polysorbate 80 to manage viscosity, oxidation risk, and volume constraints.
• Low-concentration intravenous formulations more commonly contain phosphate or citrate buffer, sodium chloride or trehalose for tonicity, and polysorbate 20 or 80.[3]

Approximately 14% of marketed mAb products are lyophilized rather than formulated as ready-to-use liquids. Lyophilized formulations rely on sucrose or trehalose as the lyoprotectant and typically include mannitol or glycine as the bulking agent for cake structure.[4]

Excipients Across Biologic Modalities: mRNA/LNP, ASOs, ADCs, AAVs, and Cell Therapies

mRNA and Lipid Nanoparticle (LNP) Formulations

Messenger RNA therapeutics and vaccines use a distinct excipient system based on lipid nanoparticles (LNPs). Standard LNP formulations contain four lipid components in defined molar ratios: an ionizable lipid (40–50 mol%), cholesterol (35–45 mol%), a helper phospholipid such as distearoylphosphatidylcholine (DSPC) (10–20 mol%), and a polyethylene glycol-lipid conjugate (PEG-lipid) (1–3 mol%).[8]

The ionizable lipid is the key functional component. It carries a positive charge below its pKa (typically pH 6.0–6.5), enabling electrostatic complexation with negatively charged mRNA during nanoparticle assembly. At physiological pH (~7.4), the ionizable lipid is deprotonated, reducing toxicity and extending circulation time. Upon cellular uptake and endosomal acidification, the lipid re-protonates, which is believed to disrupt the endosomal membrane for releasing the mRNA payload into the cytoplasm.[8]

Antisense Oligonucleotides (ASOs)

Antisense oligonucleotides (ASOs) are short, chemically modified single-stranded synthetic nucleic acids (typically 18–30 nucleotides) that modulate gene expression by binding a target RNA. Unlike mRNA, ASOs are generally not encapsulated in lipid nanoparticles. Chemical modifications to the backbone (phosphorothioate linkages) and the sugar (2′-O-methoxyethyl, 2′-O-methyl, or locked nucleic acid) confer nuclease resistance and support cellular uptake, allowing approved ASOs to be formulated as simple aqueous molecular solutions for intrathecal, subcutaneous, or intravenous administration.[9] A typical formulation contains the oligonucleotide drug substance, a buffer (commonly phosphate), a tonicity agent (sodium chloride), and water for injection, with minimal additional excipients.[10]

Because ASOs are delivered as concentrated molecular solutions rather than encapsulated particles, high-concentration formulations, particularly for subcutaneous dosing, can encounter elevated viscosity arising from intermolecular interactions of the polyanionic oligonucleotide chains, a challenge analogous to (though mechanistically distinct from) that seen in high-concentration mAbs.[10] Additional formulation considerations include controlling self-association and aggregation, managing interactions with divalent metal ions, maintaining chemical stability against hydrolysis, and meeting stringent endotoxin and particulate limits for parenteral and intrathecal routes.[11] Intrathecal products such as nusinersen are formulated preservative-free and isotonic, with an ionic composition designed to approximate cerebrospinal fluid.[12]

Antibody-Drug Conjugates (ADCs)

Antibody-drug conjugates require excipient systems that stabilize both the antibody component and the chemically labile linker connecting the cytotoxic payload. All FDA-approved ADCs are formulated as lyophilized products to minimize hydrolysis of the linker during storage.[13] Buffer pH selection is critical: formulations such as Mylotarg and Besponsa use phosphate (pH 7.5) and Tris (pH 8.0) buffers, respectively, to protect acid-sensitive hydrazone linker bonds. Sucrose or trehalose provides lyoprotection, and polysorbate provides interfacial stabilization.[13] Because all currently approved ADCs are administered intravenously after reconstitution and dilution rather than as high-concentration subcutaneous injections, they are formulated at moderate protein concentrations, so viscosity is generally not a defining concern as it is for high-concentration mAbs and ASOs; the dominant stressors are instead payload-driven hydrophobic aggregation and linker instability.[13]

Adeno-Associated Virus (AAV) Vectors

Gene therapy products based on AAV vectors present unique formulation challenges. Unlike mAbs, AAV stress conditions are not standardized across the industry, and stability behavior varies significantly by serotype.[14] AAV formulations typically include a buffer (phosphate, Tris, or histidine), a surfactant (commonly poloxamer 188), sodium chloride for tonicity, and sometimes a sugar stabilizer. The mechanisms of physical and chemical instability in AAV products, including thermal, shear, freeze-thaw, and light exposure stresses, require serotype-specific optimization rather than platform approaches.[14]

Cell Therapies

Cell therapy products (CAR-T, mesenchymal stem cells, induced pluripotent stem cells) use excipient systems focused on maintaining cell viability and osmotic balance. Buffered saline solutions are the predominant excipient, with careful control of osmolality and pH to prevent cell lysis or metabolic disruption. Cryopreservation media often include dimethyl sulfoxide (DMSO) at 5–10% v/v as a cryoprotectant, though its cytotoxicity at room temperature drives interest in DMSO-free alternatives using trehalose or combinations of sugars and polymers. The sugars in these formulations act primarily as osmotic and cryoprotective agents rather than as metabolic fuel: because cryopreservation arrests cellular metabolism at low temperatures, a carbohydrate energy source is generally not required to sustain ATP during frozen storage, although fresh or hypothermically stored products may include glucose or other nutrients to support residual metabolism over short hold times.

Polysorbate Degradation: The Defining Quality Challenge

Polysorbate degradation has emerged as one of the most intensively studied challenges in biopharmaceutical formulation science. Polysorbates degrade through two principal pathways, each producing different degradation products with distinct implications for product quality.

Hydrolytic degradation occurs primarily through enzymatic hydrolysis catalyzed by residual host cell proteins (HCPs), particularly lipases and esterases that co-purify with the drug substance. Hydrolysis cleaves the ester bond in polysorbate, releasing free fatty acids (FFAs) that are poorly soluble and can nucleate visible and subvisible particles in the formulation. The extent of FFA-driven particle formation depends on polysorbate grade (higher oleate content in PS80 correlates with different FFA profiles), enzyme type, temperature, and pH.[7,15]

Oxidative degradation is catalyzed by trace metals (iron, copper), peroxides, light exposure, and certain buffer components. Oxidation produces aldehydes, ketones, short-chain organic acids, and peroxides, which can in turn oxidize susceptible residues on the protein molecule (methionine, tryptophan). Research has demonstrated that PS80 oxidation kinetics are pH-dependent in histidine buffer, and that higher mAb concentrations can exert a protective effect against metal-catalyzed PS80 oxidation, likely by competing for catalytic metal binding sites.[7] Adding metal chelators such as EDTA or DTPA mitigates this pathway directly by sequestering the catalytic iron and copper ions, removing them from the redox cycle that drives metal-catalyzed oxidation.[7]

This dual degradation challenge has driven significant innovation in excipient quality (low-peroxide grades, super-refined polysorbates), formulation strategies (chelators, antioxidants, optimized PS concentration), and analytical monitoring throughout product shelf life. Each of these strategies targets a specific driver: low-peroxide grades and super-refined polysorbates lower the initial oxidant and impurity load, chelators bind the catalytic trace metals that would otherwise accelerate oxidation, antioxidants scavenge the reactive species once formed, and an optimized polysorbate level limits the total amount of surfactant available to degrade.

Quality Grades for Parenteral and Biologics Applications

Excipients intended for parenteral and biopharmaceutical applications must meet stringent quality standards beyond the compendial requirements (USP-NF, Ph. Eur., JP) applicable to oral dosage forms. Critical quality attributes for biologics-grade excipients include the following.

Table 3. Critical Quality Attributes for Biologics-Grade Excipients

Attribute	Requirement	Why It Matters
Endotoxin	Low endotoxin or endotoxin-free	Endotoxins cause pyrogenic reactions; parenteral products have strict limits (typically <0.5 EU/mL)
Bioburden	Low bioburden, compatible with sterile manufacturing	Minimizes risk of contamination during aseptic fill-finish
Peroxide content	Low or undetectable (especially for polysorbates, PEGs)	Peroxides catalyze oxidation of both excipients and protein API
Trace metals	Controlled (Fe, Cu, Cr, Ni)	Metals catalyze oxidation; ICH Q3D sets elemental impurity limits
Particulate matter	Meets USP <788> / Ph. Eur. 2.9.19	Subvisible particles in parenteral products are a patient safety concern
Molecular weight distribution	Controlled (for polymeric excipients: PEGs, poloxamers)	Affects viscosity, functionality, and reproducibility

Suppliers have developed specialized product lines to meet these requirements. Roquette offers Biopharma-grade mannitol (PEARLITOL), sorbitol (NEOSORB), and hydroxypropyl beta-cyclodextrin (KLEPTOSE) with guaranteed low endotoxin levels and full GMP traceability.[16] Croda’s Super Refined polysorbates undergo proprietary purification to reduce peroxide, aldehyde, and acid impurities to levels well below standard compendial monograph requirements. Merck (Sigma-Aldrich) and BASF supply parenteral-grade surfactants, buffers, and amino acids with certificates of analysis documenting endotoxin, bioburden, and trace metals.

Regulatory Framework for Biopharmaceutical Excipients

The regulatory framework for biopharmaceutical excipients spans multiple guidances and compendia, each addressing a different aspect of excipient quality, safety, and justification.

FDA Inactive Ingredient Database (IID)

The FDA Inactive Ingredient Database lists the maximum amount of each excipient per unit dose, by route of administration and dosage form, that has been approved in marketed drug products. The database is updated quarterly and serves as a benchmark for formulators: using an excipient at or below its listed maximum for the relevant route provides a degree of regulatory precedent, though it does not guarantee acceptability in a new product.[17]

ICH Q5C: Stability Testing for Biologics

ICH Q5C requires real-time, real-condition stability data as the primary basis for establishing shelf life for biotechnological products. Appropriate physicochemical, biochemical, and immunochemical methods must be used to detect degradation, including aggregation, fragmentation, charge variants, and oxidation, all of which can be influenced by excipient selection and quality.[18]

ICH Q6B: Specifications and Test Procedures

ICH Q6B defines how specifications and acceptance criteria should be set based on manufacturing process data, preclinical results, and clinical experience. Excipient-related specifications (pH, osmolality, surfactant content, particulate matter) form part of the drug product specification.[19]

ICH Q8: Pharmaceutical Development and Quality by Design

ICH Q8 provides the framework for a quality-by-design (QbD) approach to formulation development, including systematic identification of critical quality attributes (CQAs), design of experiments for excipient screening, and establishment of a design space within which excipient concentrations can vary without affecting product quality.

Pharmacopoeial Monographs (USP-NF, Ph. Eur., JP)

Pharmacopoeial monographs define identity, purity, and quality standards for individual excipients. Multi-compendial compliance (meeting the requirements of all three major pharmacopoeiae simultaneously) is standard practice for excipients used in globally marketed biologic products.

Comparison: Oral Solid Dosage Excipients vs. Biopharmaceutical Excipients

Table 4. Oral Solid Dosage Excipients vs. Biopharmaceutical Excipients

Parameter	Oral Solid Dosage Excipients	Biopharmaceutical Excipients
API type	Small molecules (typically <1,000 Da)	Proteins, nucleic acids, viral vectors (25,000–150,000+ Da)
Primary function	Mechanical (binding, filling, disintegrating, lubricating)	Molecular stabilization (preventing aggregation, oxidation, denaturation)
Route of administration	Oral	Parenteral (IV, SC, IM), intravitreal, intrathecal
Key stresses	Compression force, moisture, heat	Interfacial stress, freeze-thaw, shear, oxidation, light
Endotoxin requirements	Not typically specified	Strict limits (parenteral route)
Sterility	Not required	Required (aseptic processing or terminal sterilization)
Example excipients	Microcrystalline cellulose, lactose, magnesium stearate, croscarmellose sodium	Sucrose, histidine, polysorbate 80, arginine, trehalose
Excipient degradation concern	Moisture uptake, chemical incompatibility	Polysorbate oxidation/hydrolysis, peroxide generation, metal contamination
Regulatory precedent tool	FDA IID (oral routes)	FDA IID (parenteral routes), ICH Q5C, Q6B

Supplier Landscape for Biologics-Grade Excipients

Table 5. Selected Suppliers of Biologics-Grade Excipients

Supplier	Key Biologics-Grade Products	Specialty
Roquette	PEARLITOL (mannitol), NEOSORB (sorbitol), LYCADEX (dextrose), KLEPTOSE HPB Biopharma (HP-beta-CD)	Low endotoxin grades, full GMP traceability
Croda	Super Refined polysorbate 20, polysorbate 80, oleic acid	Proprietary purification for low peroxide, low aldehyde
Merck KGaA / MilliporeSigma	Parenteral-grade buffers, amino acids, sugars, surfactants	Broad portfolio, Emprove dossiers for regulatory filing support
BASF	Kollidon (povidone), Kolliphor (poloxamers, PEG derivatives)	Parenteral-grade poloxamer 188, PEG variants
Pfanstiehl	High-purity, low-endotoxin trehalose, sucrose, mannitol, arginine HCl	Ultra-low endotoxin (<0.01 EU/mg), specifically designed for biologics
Ferro Pfanstiehl / FUJIFILM Wako	Histidine, methionine, proline for injection	Amino acid purity for parenteral use

FAQs

What is the difference between a biopharmaceutical excipient and a pharmaceutical excipient?

Biopharmaceutical excipients stabilize large biomolecules (proteins, nucleic acids, viral vectors) against aggregation, oxidation, and denaturation in injectable formulations. Conventional pharmaceutical excipients serve mechanical and release-controlling functions in oral solid dosage forms such as tablets and capsules. Both categories are inactive ingredients, but the stresses they address and the quality grades they require differ substantially, particularly regarding endotoxin limits and sterility.

Why are polysorbates used in almost all monoclonal antibody formulations?

Polysorbates (PS20 and PS80) protect monoclonal antibodies from aggregation caused by adsorption to air-liquid and ice-liquid interfaces during manufacturing and storage. They appear in approximately 94% of high-concentration mAb products because no alternative surfactant has demonstrated equivalent performance across the range of processing stresses encountered in commercial biologics manufacturing. Poloxamer 188 is the primary alternative, used in some products where polysorbate degradation risk is deemed too high.[3]

What is preferential exclusion, and why does it matter for biologics?

Preferential exclusion is the thermodynamic mechanism by which sugars (sucrose, trehalose) and polyols stabilize proteins. These excipients are excluded from the protein’s hydration shell, increasing the energetic cost of protein unfolding. This shifts the folding equilibrium toward the native, functional conformation, providing protection against thermal and conformational stresses during storage and lyophilization.[2]

What quality grades of excipients are required for injectable biologics?

Injectable biologic products require excipients manufactured to parenteral or biologics-grade standards, including low endotoxin levels (typically <0.5 EU/mL in the final product), low bioburden, controlled trace metals (per ICH Q3D), and, for polysorbates and polyethylene glycols, low peroxide content. Standard compendial (USP/Ph. Eur.) grades designed for oral use may not meet these requirements without additional purification.

How do excipient needs differ between liquid and lyophilized biologic formulations?

Liquid formulations rely primarily on stabilizers (e.g. sucrose, arginine), surfactants (e.g. polysorbate), and buffers (e.g. histidine) to maintain protein stability in solution over shelf life. Lyophilized formulations additionally require a bulking agent (e.g. mannitol, glycine) to form a mechanically stable cake and a lyoprotectant (e.g. sucrose, trehalose) to replace water hydrogen bonds during drying and maintain protein structure in the solid state.[5]

What excipients are used in mRNA lipid nanoparticle formulations?

Messenger RNA-LNP formulations use at least four lipid excipients: an ionizable lipid (40–50 mol%) for mRNA encapsulation and endosomal escape, cholesterol (35–45 mol%) for structural rigidity, a helper phospholipid (10–20 mol%) for bilayer stability, and a PEG-lipid (1–3 mol%) to extend circulation time and prevent opsonization. These are fundamentally different from the protein-stabilizing excipients used in mAb formulations.[8]

Why is polysorbate degradation such a significant concern in biologics?

Polysorbate degradation produces free fatty acids (from enzymatic hydrolysis by residual host cell proteins) and reactive aldehydes and peroxides (from oxidation). Free fatty acids are poorly soluble and nucleate visible and subvisible particles that can trigger immune responses. Oxidation products can damage the protein API itself. Managing polysorbate stability requires controlling host cell protein levels, using low-peroxide excipient grades, adding chelators, and monitoring degradation throughout shelf life.[7,15]

What regulatory guidance applies to excipient selection for biologics?

Excipient selection for biologics is governed by the FDA Inactive Ingredient Database (for precedent of use by route), ICH Q5C (stability requirements for biologics), ICH Q6B (specifications and test procedures), ICH Q8 (pharmaceutical development and QbD), and pharmacopoeial monographs (USP-NF, Ph. Eur., JP) for individual excipient quality standards. Excipient choice must be justified in the Chemistry, Manufacturing, and Controls (CMC) section of regulatory filings.[17,18,19]

Key Takeaways

Biopharmaceutical excipients protect structurally fragile biomolecules from aggregation, oxidation, and denaturation, serving a fundamentally different role than the mechanical excipients used in oral solid dosage forms.

Histidine (~80%), sucrose (~50%), polysorbate (~90%), and arginine (~30%) dominate current commercial monoclonal antibody formulations, reflecting the industry’s convergence on a proven excipient platform.[3]

Preferential exclusion, interfacial competition, and colloidal stabilization are the three primary mechanisms by which biopharmaceutical excipients maintain protein stability.

Polysorbate degradation (both enzymatic hydrolysis and oxidation) remains the defining quality challenge, driving demand for low-peroxide grades, chelators, and advanced analytical monitoring.

Biologics-grade excipients must meet stringent requirements for endotoxin, bioburden, trace metals, and peroxide content that go beyond standard compendial specifications for oral dosage forms.

Excipient needs vary significantly across biologic modalities: mAb formulations, mRNA/LNP systems, ASOs, ADCs, AAV vectors, and cell therapies each require distinct excipient strategies tailored to their unique degradation and stability pathways.

The regulatory framework (FDA IID, ICH Q5C/Q6B/Q8, pharmacopoeial monographs) requires science-based justification for every excipient selected in a biologic drug product.

Sources

1. Consegic Business Intelligence. “Biopharmaceutical Excipients Market Size, Drivers & Opportunities 2032.” Accessed April 2026. https://www.consegicbusinessintelligence.com/biopharmaceutical-excipients-market
2. Pramanick S, Singodia D, Chandel V. “A Comprehensive Scientific Survey of Excipients Used in Currently Marketed, Therapeutic Biological Drug Products.” Pharm. Res., 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9010397/
3. Svilenov HL, et al. “A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations.” mAbs, 2023;15(1):2205540. https://pmc.ncbi.nlm.nih.gov/articles/PMC10228404/
4. Duarte AC, et al. “Monoclonal antibody formulations: a quantitative analysis of marketed products and patents.” mAbs, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12578304/
5. BioPharm International. “For Lyophilization, Excipients Really Do Matter.” Accessed April 2026. https://www.biopharminternational.com/view/lyophilization-excipients-really-do-matter
6. Finkler C, Bhatt S. “Interfacial Stress in the Development of Biologics: Fundamental Understanding, Current Practice, and Future Perspective.” AAPS J., 2019;21(3):44. https://pmc.ncbi.nlm.nih.gov/articles/PMC6435788/
7. “Oxidation of polysorbates – An underestimated degradation pathway?” Eur. J. Pharm. Biopharm., 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10480556/
8. “Composition of lipid nanoparticles for targeted delivery: application to mRNA therapeutics.” Front. Pharmacol., 2024. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1466337/full
9. Ersöz E, Demir-Dora D. “Unveiling the potential of antisense oligonucleotides: Mechanisms, therapies, and safety insights.” Drug Dev. Res., 2024;85:e22187. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/ddr.22187
10. Poecheim J, Graeser KA, Hoernschemeyer J, et al. “Development of stable liquid formulations for oligonucleotides.” Eur. J. Pharm. Biopharm., 2018;129:80–87. https://pubmed.ncbi.nlm.nih.gov/29802983/
11. Lim M, Dibble A. “Osmolality of antisense oligonucleotide parenteral formulations: implications on counterion dissociation and recommended osmometry techniques.” Int. J. Pharm., 2017;515(1–2):788–799. https://pubmed.ncbi.nlm.nih.gov/27989829/
12. FDA. “SPINRAZA (nusinersen) injection, for intrathecal use — Prescribing Information.” 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209531lbl.pdf
13. “Fundamental properties and principal areas of focus in antibody-drug conjugates formulation development.” Antibody Therapeutics, 2025;8(2):99. https://academic.oup.com/abt/article/8/2/99/8064716
14. “Drug product Formulation and Fill/Finish Manufacturing Process Considerations for AAV-Based Genomic Medicines.” J. Pharm. Sci., 2024. https://www.sciencedirect.com/science/article/abs/pii/S0022354924001254
15. “Polysorbates degrading enzymes in biotherapeutics – a current status and future perspectives.” Front. Bioeng. Biotechnol., 2024. https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2024.1490276/full
16. Roquette. “Excipients’ Attributes Crucial for Parenteral Preparation.” Accessed April 2026. https://www.roquette.com/health-pharma/resources/excipients-attributes-parenteral-preparation
17. FDA. “Inactive Ingredient Database Download.” Accessed April 2026. https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredients-database-download
18. ICH. “Q5C: Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products.” https://database.ich.org/sites/default/files/Q5C%20Guideline.pdf
19. ICH. “Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products.” https://database.ich.org/sites/default/files/Q6B%20Guideline.pdf

---

Disclaimer: This article is intended for biopharmaceutical formulation, process, and regulatory professionals. It does not constitute clinical, regulatory, or formulation advice. Always refer to the current pharmacopoeial monograph, the supplier’s current technical data sheet and Certificate of Analysis, applicable ICH/FDA/EMA guidance, and your own development and stability data. Pharma Excipients International AG is not a manufacturer of the excipients discussed.

---

Read our article on mRNA Formulation Challenges: